Composition, form of production and packaging
? Tablets from white to white with a yellowish shade of color, round, plane-cylindrical, with a facet and engraved with the letters "Ch" on one side.
1 tab.
gimecromone 200 mg
Auxiliary substances: potato starch - 45 mg, gelatin - 3 mg, sodium lauryl sulfate - 1 mg, magnesium stearate - 1 mg.
10 pieces. - blisters (5) - packs of cardboard.
50 pcs. - blisters (1) - packs of cardboard
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2013.
PHARMACHOLOGIC EFFECT
Cholagogue preparation. Increases the formation and secretion of bile. Has a selective antispasmodic effect on the bile duct and sphincter of Oddi. The drug does not reduce the peristalsis of the gastrointestinal tract and blood pressure.
Reduces stagnation of bile, prevents the crystallization of cholesterol and thus the development of cholestasis.
PHARMACOKINETICS
Suction and distribution
After oral administration, it is rapidly absorbed from the digestive tract. C max in the blood after ingestion is achieved after 2-3 hours.
Poorly binds to plasma proteins.
Excretion
T 1/2 is about 1 hour. It is excreted in urine: about 93% in the form of glucuronate, 1.4% in the form of sulfonate, 0.3% in unchanged form.
INDICATIONS
- dyskinesia of bile ducts and sphincter of Oddi in hyperkinetic type;
- Non-calculous chronic cholecystitis, cholangitis, cholelithiasis;
- condition after surgery on the gallbladder and biliary tract;
- decreased appetite, nausea, constipation, vomiting (against the background of hypoxecretion of bile).
DOSING MODE
The drug is prescribed inside for 30 minutes before meals.
Adults appoint 200-400 mg 3 times / day. The daily dose is 1200 mg. The course of treatment is 2 weeks.
SIDE EFFECT
On the part of the digestive system: diarrhea, flatulence, abdominal pain, ulceration of the gastrointestinal mucosa.
Other: allergic reactions, headache.
CONTRAINDICATIONS
- obstruction of the biliary tract;
- kidney failure;
- liver failure;
- ulcerative colitis;
- Crohn's disease;
- Stomach ulcer and duodenal ulcer;
- hemophilia;
- children's age till 18 years;
- Hypersensitivity to the components of the drug.
PREGNANCY AND LACTATION
There is no data on the safety of gemecromone during pregnancy and lactation.
The appointment of Odeston during pregnancy and lactation (breastfeeding) is only permissible if the intended benefit to the mother exceeds the potential risk to the fetus or child.
APPLICATION FOR FUNCTIONS OF THE LIVER
Contraindicated in severe impairment of kidney function.
APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
Contraindicated in severe violations of liver function.
APPLICATION FOR CHILDREN
Contraindicated in children and adolescents under 18 years.
SPECIAL INSTRUCTIONS
Does not impair the secretory function of the digestive glands and intestinal absorption processes.
Impact on the ability to drive vehicles and manage mechanisms
The drug does not affect the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
OVERDOSE
Odeston was not reported at the time of overdose.
DRUG INTERACTION
With the simultaneous use of morphine, which causes spasm of the sphincter of Oddi, weakens the effect of Odeston.
With the simultaneous use of Odeston and metoclopramide, there is a mutual weakening of the effect.
Odeston enhances the effects of indirect anticoagulants.
TERMS OF RELEASE FROM PHARMACY
The drug is approved for use as a means of OTC.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored out of the reach of children at a temperature of no higher than 25 В° C. Shelf life - 3 years.
